The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > Physiogenex to present its 3-week ultra-fast NASH screening mouse model at the AASLD Liver Meeting 2018

News detail

Return to all news & events

11/08/2018 Physiogenex to present its 3-week ultra-fast NASH screening mouse model at the AASLD Liver Meeting 2018

Physiogenex will be presenting its 3-week ultra-fast NASH screening mouse model mouse at the Liver Meeting 2018, in San Francisco, November 9th-13th, 2018.

The effects of GLP-1 receptor agonists in this innovative NASH mouse model will be presented by Dr. François Briand, Director of Research and Business Development, during the poster session on Sunday, November 11th, 12:30am-2:00pm, poster#1827.

If you want to set an appointment during the Liver Meeting with Dr. François Briand to discuss about your NASH projects, please contact us !